SELVAS Healthcare Launches AI-based Body Composition Analyzer 'ACCUNIQ BC380' Worldwide

-Intelligent body composition analyzer based on latest information technology and US clinical test results

-Industry’s first after-sales remote support program to enable remote tech support anywhere in the world

SELVAS Healthcare's AI-based Body Composition Analyzer ACCUNIQ BC380 (Photo: Business Wire)

SEOUL, South Korea--()--SELVAS Healthcare (KOSDAQ:208370) has launched a next generation body composition analyzer ACCUNIQ BC380.

ACCUNIQ BC380 is a next-generation intelligent body composition analyzer, which reflects the digital healthcare company’s accumulated product development know-how, cutting-edge information technology and the findings of consumer researches conducted in step with market trends and US clinical test results.

The new analyzer has further raised the accuracy of body composition measurement through its high correlation with Dual Energy X-ray Absorptiometry (DEXA) at a US clinical trial center IHT. It also applied innovative software technologies to product design, UI screens and result sheets.

The industry’s first after-sales service ‘ACCUNIQ Remote Support’ connects users to the customer service department of SELVAS Healthcare remotely from anywhere around the world. As a result, ACCUNIQ BC380 can be diagnosed, repaired and upgraded more easily.

The new product also offers personalized diet and exercise prescriptions personalized on the basis of measurement data in conjunction with ACCUNIQ Manager, proprietary software to manage individual user’s body composition data. It can be linked with a series of ACCUNIQ ultrasound height meter and fully automatic blood pressure monitors.

“By launching ACCUNIQ BC380, we plan to set a new industry standard for body composition analyzers in the global market,” SELVAS Healthcare CEO Ken B. Yoo said, “Our goal is to become a leading digital healthcare company by integrating our expertise in body composition analysis, artificial intelligence and IoT technologies.”

ACCUNIQ BC380 will be exhibited at the MEDICA 2017 (Booth No.11F67), in Dusseldorf, Germany from November 13~16.

SELVAS Healthcare, Inc. was listed on KOSDAQ in September 2016 after it was renamed from Jawon Medical Co., a leading medical device manufacturer since 1993. SELVAS Healthcare has been solidifying its position in the global medical device market by releasing innovative products based on the AI technology of its subsidiary SELVAS AI. Its major products include ACCUNIQ BP850 (a.k.a. EX PLUS 1300), world’s first dual-arm blood pressure monitor which can measure the blood pressures difference between both arms, body composition analyzers, braille terminals, video magnifiers and text-to-speech voice readers.

Contacts

SELVAS Group
Kate Kim, +82-2-6190-7676
kate.e.kim@selvas.com

Release Summary

SELVAS Healthcare launched AI-based Body Composition Analyzer 'ACCUNIQ BC380' based on latest information technology and US clinical test results.

Social Media Profiles

Contacts

SELVAS Group
Kate Kim, +82-2-6190-7676
kate.e.kim@selvas.com